Simple, mammalian cell-based assay for identification of inhibitors of the Erk MAP kinase pathway
暂无分享,去创建一个
[1] E. Krebs,et al. The MAPK signaling cascade , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[2] P. LoRusso,et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] A. Hampl,et al. FGF2 inhibits proliferation and alters the cartilage-like phenotype of RCS cells. , 2004, Experimental cell research.
[4] P. Russo. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma , 2006 .
[5] Thomas D. Y. Chung,et al. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.
[6] J. Lyons,et al. Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. , 2005, Current opinion in pharmacology.
[7] J. Pouysségur,et al. Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[8] M. Knowles,et al. Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. , 2005, Experimental cell research.
[9] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[10] H. Prats,et al. Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis , 2005, Journal of Cell Science.
[11] C. Marshall,et al. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells , 1994, Cell.
[12] E. Laplantine,et al. Activation of the ERK1/2 and p38 Mitogen-activated Protein Kinase Pathways Mediates Fibroblast Growth Factor-induced Growth Arrest of Chondrocytes* , 2004, Journal of Biological Chemistry.
[13] V. Lefebvre,et al. Use of a New Rat Chondrosarcoma Cell line to Delineate a 119-Base Pair Chondrocyte-specific Enhancer Element and to Define Active Promoter Segments in the Mouse Pro-α1(II) Collagen Gene (*) , 1995, The Journal of Biological Chemistry.
[14] L. Thompson,et al. Bisindolylmaleimide I Suppresses Fibroblast Growth Factor-mediated Activation of Erk MAP Kinase in Chondrocytes by Preventing Shp2 Association with the Frs2 and Gab1 Adaptor Proteins* , 2007, Journal of Biological Chemistry.
[15] R. Assoian,et al. Integrating the MAP kinase signal into the G1 phase cell cycle machinery. , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.
[16] D. Strumberg,et al. Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] J. Hecht,et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.